

17 November 2006

To All Pharmaceutical Suppliers, Hospital Pharmacists, Medical Groups and  
Interested Parties

## Consultation on provisional agreement with Mayne Pharma Pty Limited for various pharmaceuticals on the Pharmaceutical Schedule

Following a request for Alternative Commercial Proposals as part of the 2006/07 Tender consultation, PHARMAC and Mayne Pharma Pty Limited have entered into a provisional agreement for amendments of the terms of listing for various pharmaceuticals in Sections B and H of the Pharmaceutical Schedule from various dates from 1 February 2007. We note that all pharmaceuticals in this provisional agreement are currently being supplied by Mayne Pharma Pty Limited.

We are now seeking feedback on this proposal. Key aspects of the proposal are as follows:

- It is proposed that the listing of the following pharmaceuticals in Section B and Section H of the Pharmaceutical Schedule (as applicable) are amended from the 1 February 2007 as follows:

Pharmaceutical	Form	Strength	Pack Size	Brand	Current Price and Subsidy	Proposed Price and Subsidy
Cisplatin	Injection	1 mg per mL, 50 mL	1	Mayne	59.20	\$19.00
Cisplatin	Injection	1 mg per mL, 100 mL	1	Mayne	116.00	\$38.00
Cytarabine	Injection	100 mg per mL, 5 mL	5	Mayne	\$355.00	\$95.36
Cytarabine	Injection	100 mg per mL, 10 mL	1	Mayne	\$75.00	\$42.65
Cytarabine	Injection	100 mg per mL, 20 mL	1	Mayne	\$118.00	\$34.47
Etoposide	Injection	20 mg per mL, 5 mL	1	Mayne	\$39.95	\$25.00
Naloxone hydrochloride	Injection	400 mcg per mL, 1 mL	5	Mayne	\$27.00	\$33.00

Prices and subsidies are ex-manufacturer, ex-GST.

- It is proposed that the listing of the following pharmaceutical in Section B and Section H of the Pharmaceutical Schedule is amended from the 1 July 2007 as follows:

Pharmaceutical	Form	Strength	Pack Size	Brand	Current Price and Subsidy	Proposed Price and Subsidy
Frusemide	Injection	10 mg per mL, 2 mL	50	Mayne	\$41.00	\$29.50

Prices and subsidies are ex-manufacturer, ex-GST.

- The provisional agreement includes subsidy, price and delisting protection for all the pharmaceuticals listed above until 30 June 2010.

It is anticipated that the proposed changes, if approved by PHARMAC's Board, or Acting Chief Executive under delegated authority, would take effect from 1 February 2007 (or later where applicable). If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to Jackie Evans at PHARMAC by **5:00 pm, 1 December 2006**. All comments submitted by this date will be considered.

Yours sincerely



Jackie Evans  
Therapeutic Group Manager